Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (5790)	12/21/1998 9:35:00 PM
From: billkirn	Read Replies (1) \| Respond to of 6136

Henry: Shorts have lost over $200 Million since Sept. Will they panic? Bill

To: Henry Niman who wrote (5790)	12/21/1998 11:18:00 PM
From: Oliver & Co	Respond to of 6136

"Glaxo Wins Approval for New AIDS Drug Despite Serious Risks" Wall Street Journal (12/21/98) P. B8 Glaxo Wellcome's newest AIDS drug, Ziagen, was approved for marketing by the Food and Drug Administration Thursday, even though clinical trials showed that about 5 percent of patients experienced significant, and in some cases, fatal side effects, including fever, nausea, abdominal pain, low blood pressure, and an enlarged liver. Despite the potential drawbacks, the FDA approved Ziagen because it is used to treat a life-threatening disease and may allow some patients to discontinue the use of drug "cocktails" that are the standard in AIDS treatment today. While many patients currently take as many as 20 pills a day, patients who can tolerate Ziagen in combination with another AIDS drug, such as Glaxo's Combivir, would have to only take about four pills a day. Ziagen, a nucleoside analogue reverse transcriptase inhibitor, is the fourth AIDS drug Glaxo has developed.